Short Communication
Can Advances in Immunotherapy Improve the Survival in Women with Recurrent Cervical Cancer?
Heather R Williams and Sharad Ghamande*
Department of Gynecologic Oncology, Georgia Cancer Center, USA
*Corresponding author: Sharad Ghamande, Department of Gynecologic Oncology, Georgia Cancer Center, USA
Published: 15 Dec, 2017
Cite this article as: Williams HR, Ghamande S. Can
Advances in Immunotherapy Improve
the Survival in Women with Recurrent
Cervical Cancer?. Clin Oncol. 2017; 2:
1384.
Short Communication
Cervical cancer is the second leading cause of female cancer related deaths in the world with
an estimated 266,000 lives lost each year [1,2]. An estimated 2.27 million women worldwide have
cervical cancer at any given moment in time and approximately 528,000 new women are diagnosed
each year worldwide [2]. The brunt of the diagnosis, a staggering 80%, occurs in developing
countries [2]. Due to advances in screening techniques and public awareness, the overall rate of
cervical cancer in the United States has declined. However there are still approximately 12,500 new,
cases of cervical cancer diagnosed each year and 4,100 women die from their disease each year [3].
Additionally, it is estimated that over 300,000 women in the United States have a diagnosis of CIN
2/3, the precursor to cervical cancer [4].
The Human Papilloma Virus (HPV) is the oncogene virus responsible for the development of
cervical dysplasia and progression to cancer. HPV is small double stranded DNA virus and infection
leads to a loss of cell cycle regulation and a resistance to apoptosis [5,6]. This causes increased genetic
instability and cell proliferation. Tumor suppressor proteins are then sequestered and the HPV
virus is integrated in the cellular DNA. This leads to up regulation of viral oncogenes and increased
chromosomal abnormalities with activation of telomerases [7]. E6 and E7 are the oncogenes that
bind p53 and retinoblastoma proteins to facilitate inhibition of tumor suppression of the 12 highrisk
subtypes, 16, 18 are responsible for 70% of all cervix cancer [5].
Primary disease
Unlike most of gynecological cancers that require surgical staging, cervical cancer remains a
clinically staged disease, wherein CT or PET imaging findings do not influence the stage. Primary
treatment either involves surgery for early stage and chemo radiation for advanced stage cervix
cancer [8]. Stage 1A1 cancers can be managed with either cold knife cone in the event fertility is
desired or simple hysterectomy whereas stages 1A2 to 1B1 are mostly managed with a modified
radical hysterectomy and a pelvic node dissection. Occasionally, IA2 to IB1 can also be managed
with radical trachelectomy when fertility is desired in select women with small tumors less than 2cm
and absence of Lympho Vascular Space Invasion (LVSI). Most stage 1B2 and above are treated with
cisplatin based chemo radiation. Five year survival is estimated between 80-93% for stage I, 58-63%
for stage II, 32-25% for stage III and 15-16% for stage IV [9].
A look at the probability of surviving recurrence-free in advanced stage cancer for at least 3
years is discouraging. The estimated survival probabilities are 69%, 33%, 56% and 10% for subjects
with stage 2B, 3A, 3B and 4A disease respectively [10]. Additionally women with early clinical stage
and positive lymph nodes also prognostically do poorly. Ina study with subjects with advanced
cervical cancer who are surgically staged and then treated with radiotherapy, 5-year PFS was 57%
for node-negative subjects but decreased to 34% and 12% for subjects with pelvic and para-aortic
lymph node metastases, respectively [11]. The four-year risk of death and recurrence for these node
positive women and patients with advanced stage cervix cancer is 50% [11]. These statistics are
staggering and highlight the need of better treatment options for these patients for both prevention
and treatment of recurrent disease.
Recurrent disease
In 2011 Duenas-Gonzalez et al. reported a 9% improvement in PFS by adding concurrent
gemcitabine to weekly cisplatin during radiation followed by 2 additional cycles of cisplatingemcitabine
[12]. Unfortunately, there remains a high rate of recurrence following primary
treatment and currently there are limited treatments available for recurrent disease. This unmet need
is highlighted by the fact that there are actually only three single agent chemotherapy regimens that
are FDA approved for treatment of recurrent cervical cancer which
are Bleomycin, Topotecan and Bevacizumabin last 50 years, with
cisplatin-gemcitabine being the only approved combination [13].
From 1998 through 2015, there were greater than 20 Phase 2 studies
involving persistent or recurrent metastatic cervical cancer conducted
by the Gynecologic Oncology Group (GOG). Until recently, only one
study had met the predefined efficacy and safety threshold to progress
to second stage of enrollment. Monk et al. found that Bevacizumab
demonstrated a median OS of 7.3 months and at 12-months OS was
equal to 30% [14]. Then in 2014, results from GOG 240 demonstrated
that addition of bevacizumab to single agent chemotherapy compared
to single agent therapy aloneimproved OS with median OS of 16.8
months compared to 13.3 months in recurrent disease [HR=0.765
(95% CI, 0.62-0.95) p=0.0068] [15]. While this was a significant gain
in meaningful OS, there remains an enormous need for new novel
therapies that can provide meaningful progression free periods and
improve overall survival for patients with advanced or recurrent
cervical cancer.
Novel therapies on the horizon
One of the promising new therapies that could change the course of
persistent or recurrent cervical cancer is immunotherapy, leveraging
a patient’s own immune system to fight cancer. It is an attractive
strategy for cervical cancers because these tumors nearly universally
harbor the HPV E6 and E7 antigens. E6 and E7 are appealing
therapeutic targets because they are constitutively expressed, tumor
specific, and functionally important, and they can be recognized and
attacked by the human adaptive immune system. Currently, there are
four classes of immunotherapy treatments; adoptive T cell therapy,
monoclonal antibodies, checkpoint inhibitors and vaccines.
Adoptive T-cell therapy
T-cell therapy is utilized by removing a patient’s T-cells,
genetically modifying them and then reintroducing them into the
patient with the goal of improving T-cell recognition and anticancer
response. In a provocative study by Hinrichs et al, patients
with a diagnosis of metastatic cervical cancer and previous platinum
based chemotherapy or chemo radiation had surgically harvested
tumor infiltrating lymphocytes [16]. The patients then underwent
lymphocyte-depleting chemotherapy, augmentation with IL2 and
then were treated with a single infusion of “tumor-infiltrating T-cells”
(TILs) that had been selected for HPV E6 and E7 [16] reactivity. Three
out of nine patients experienced objective tumor responses, two with
complete responses and the other with a partial response [16]. The two
complete responses were ongoing 22 and 15 months after treatment,
respectively with a partial response of 3 months. The HPV reactivity
of T-cells in the infusion product as measured by interferon gamma
production, enzyme linked immune spot and CD137 up regulation
assays correlated positively with clinical response (p=0.0238 for
all three assays) [16]. Additionally, the frequency of HPV reactive
T-cells in the peripheral blood 1 month after treatment was positively
associated with clinical response (p=0.0238) [16]. Similar phase 2
trials are now currently underway time for TILs therapy.
Monoclonal antibodies
Antibodies are proteins that fight infection and our body
produces them when it detects a toxin or foreign substance known
as an antigen. Monoclonal antibodies are made in a laboratory and
designed to attack a specific cancer protein and in immunotherapy,
they are designed to attach itself to a specific cancer protein that would
enable the immune system to recognize the cancer cell and attack
it. Currently ongoing trials with available monoclonal antibodies
with activity directed at cervical cancers include HuMax®-TF-ADC,
an antibody drug conjugate targeting tissue factor-specific cells
and are being tested in two clinical trials in patients with advanced
cancer including cervical cancer (NCT02001623, NCT02552121).
Additionally, IMMU-132, (TisotumabVedotin) is an antibody drug
conjugate targeting the TROP-2 antigen, which is expressed in a
variety of cancers, and is being tested in a phase I/II trial in patients
with advanced cancer, including cervical cancer (NCT01631552).
Immune checkpoint inhibitors
Immune checkpoint inhibitors work by targeting molecules
which serve as the “checks and balances” in the regulation of T-cells
or those molecules which inhibit T-cells and prevent them attacking
native cells [17]. The checkpoint is a protein on the cell that signals
the T-cells not to attack. A checkpoint inhibitor is designed to remove
this mechanism from cancer cells thereby allowing the T-cells to
identify and attack them. Preliminary results from the phase II
KEYNOTE-158 study using pembrolizumab , a humanized antibody
that targets PD L1 receptor demonstrate, among patients with
recurrent or metastatic cervical cancer a overall response rate of 11%,
and another 30% of patients had stable disease [18]. 87% of patients
had PD1expression on immune histochemistry, 52% of patients had
2 or more prior lines of therapy [18]. The median time to their noted
response was 2.1 months (range 1.6 to 4.2 months) and 100% of the
10 responding patients had not had disease progression for a time
range 4.2 to 8.7 months [18]. The drug is well tolerated and the study
is ongoing but holds promise that for a subset of patients with PD-L1
positive tumors.
GOG 9929 is a completed phase 1 study that showed the safety of
using Ipilimumab, a monoclonal antibody that activates the immune
system by targeting CTLA-4, a protein receptor that down regulates
the immune system, in patients with early cervix cancer and positive
nodes or with advanced disease as a consolidation strategy to reduce
recurrence rates [19].
Vaccine therapy
Vaccine therapy for prevention of cervix cancer had now become
main stream, with increasing rates of vaccination all across the US.
These include 3 FDA approved HPV vaccines; Gardasil, Gardasil 9
and Cervarix, all of which have remarkable efficacy and safety data in
preventing cervix and other HPV related cancer such as vulva, vagina
and anal cancer [4]. They are currently approved for administration
from age 9 years until 26 years [4]. A breakthrough in the development
of HPV vaccines was the observation that the major capsid protein
(or the L1 protein) could self-assemble into noninfectious viruslike
particles [20]. Virus-like particles closely resemble live virus
morphologically and can induce high titers of antibodies against
live HPV types. VLPs are nontoxic, immunogenic and possess no
oncogenic potential. Several phase II trials using various types of
HPV vaccines have been completed and presently, several phase III
HPV vaccine trials are underway.
One therapeutic vaccine that has shown promise in phase I-II
trials is the vaccine ADXS11-01 (axali-mogene filolisbac). It is a
vaccine that consists of live attenuated Listeria monocytogenes
that has been modified to secrete an HPV16-E7 fusion protein.
When this is recognized, T helper cell immunity is triggered and
cytotoxic T cells are recruited to target the HPV-E7 cells in the
tumor. Additionally, it simultaneously suppresses the immunologic
defenses within the lesions, by decreasing T reg and MDSC’s in the
tumor microenvironment [21]. In a phase II study of Indian women
with recurrent cervical cancer randomized to receive ADXS11-01for
3 doses with or without concurrent cisplatin, Petit et. al found that
12-month OS was 32% with a RR of 11%and disease control rate
of 38% [21]. Additionally, cisplatin improved toxicity but did not
improve survival or tumor response.
This data was confirmed by a subsequent trial GOG 265, that
enrolled 46 patients in a 2 step phase II trial in women with recurrent,
previously treated cervical cancer [22].52% of all patients had 2 or
more prior lines of therapy, 56 % had prior bevacuzimab and 86 %
had prior radiation therapy. The 12 month OS was 38 %, the highest
OS seen over 20 years of phase II trials in cervical cancer by the GOG
in second line setting, where the average survival is 4-7 months [14].
The clinical benefit was seen in 32% of patients with one complete
response which is ongoing for over 24 months. The vaccine was
generally well tolerated with a 10% of patients experiencing a grade 3
Cytokine Release Syndrome (CRS) [22].
There is a phase III trial in the process of being launched, with
the vaccine combination with a PDL1 targeting checkpoint inhibitor.
The vaccine is also available in a large phase 3 trial in a consolidation
setting to prevent recurrence in patients with advanced cervix cancer
after chemo radiation. This study is a double blind placebo controlled
randomized trial that randomizes patients 1:2 to receive the placebo
or the ADXS11-001 vaccine for a year and is currently accruing
patients.
Conclusion
In conclusion, while great strides have been made in improving screening and prevention for cervical cancer, the recurrence rates for node positive early and locally advanced cervical cancer remains unacceptably high [11]. Additionally, treatment options currently available for patients diagnosed with recurrent disease are limited in efficacy. While many studies are underway in recurrent cervical cancer, immunotherapy is an area that holds promise to turn the tide in the treatment of this disease.
References
- Women's Health. World Health Organization. [Online]. 2017.
- Cervical Cancer. World Health Organization. [Online]. 2017.
- United States Cancer Statistics: 1999–2014 Incidence and Mortality Web-based Report. Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute. Atlanta. 2017.
- Saslow D, Castle PE, Cox JT, Davey DD, Einstein MH, Ferris DG et.al. American Cancer Society Guideline for Human Papilloma Virus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin. 2007;57(1):7-28.
- Yim EK, Park JS. The Role of HPV E6 and E7 Oncoproteins in HPV - associated Cervical Carcinogenesis. Cancer Res Treat. 2005;37(6):319-24.
- Crook T, Tidy JA, Vousden KH. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell. 1991;67(3):547-56.
- Ferris DG, Cox JT, O'Connor DM. Modern colposcopy: textbook and atlas (2nd edition). Dubuque, IA : Kendall/Hunt Publishing Company. 2004.
- NCCN Practice Guidelines in Oncology-Cervical Cancer. [Online] 2017.
- Edge S B, Compton C C. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471-4.
- Rose PG, Ali S, Watkins E, Thigpen JT, Deppe G, Clarke-Pearson DL et.al. Long-Term Follow-Up of a Randomized Trial Comparing Concurrent Single Agent Cisplatin, Cisplatin-Based Combination Chemotherapy, or Hydroxyurea During Pelvic Irradiation for Locally Advanced Cervical Cancer: A Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(19):2804-10.
- Lanciano, Rachelle, Corn, BW. The Role of Surgical Staging for Cervical Cancer. Seminars in radiation oncology. 1994;4(1):46-51.
- Dueñas-González A, Zarbá JJ, Patel F, Alcedo JC, Beslija S, Casanova L et.al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol. 2011;29(13):1678-85.
- Drugs Approved for Cervical Cancer. National Cancer Institute. [Online] 2017.
- Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE, Roman LD. Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study. J Clin Oncol. 2009;27(7):1069-74.
- Krishnansu S. Tewari, Michael W. Sill, Harry J. Long, III, Richard T. Penson, Helen Huang, Lois M. Ramondetta et.al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370:734-43.
- Stevanović S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol., 2015;33(14):1543-50.
- Turnis ME, Andrews LP, Vignali DA. Inhibitory receptors as targets for cancer immunotherapy. European journal of immunology. Eur J Immunol. 2015;45(7):1892-905.
- Jan H.M. Schellens, Aurelien Marabelle, Susan Zeigenfuss, Jie Ding, Scott Knowles Pruitt, Hyun Cheol Chung. Pembrolizumab for previously treated advanced cervical squamous cell cancer: Preliminary results from the phase 2 KEYNOTE-158 study. J Clin Oncol. 2017;35(15):5514.
- Jyoti Mayadev, William E. Brady, Yvonne Gail Lin, Diane M Da Silva, Heather A. Lankes, Paula M. Fracasso et.al. A phase I study of sequential ipilimumab in the definitive treatment of node positive cervical cancer: GOG 9929. J Clin Oncol. 2017;35(15):5526.
- Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. The Lancet. 2007;369(9578):1861-8.
- Robert G Petit, Ajay Mehta, Minish Jain, Sudeep Gupta, Rajnish Nagarkar, Vijay Kumar et al. ADXS11-001 immuno- therapy targeting HPV-E7: final results from a phase 2 study in Indian women with recurrent cervical cancer. J Immunother Cancer. 2014;2:92.
- Warner King Huh, Don S. Dizon, Matthew A. Powell, Charles A. Leath, Lisa Michelle Landrum, Edward Tanner, et al. ADXS11-001 immunotherapy in squamous or non-squamous persistent/recurrent metastatic cervical cancer: Results from stage 1 (and stage 2) of the phase II GOG/NRG-0265 study. J Clin Oncol. 2016;34(15):5516.